Study: 18F-FLT helps track patients' response to treatment

10/8/2009 | HealthImaging.com

An Australian study that compared results of baseline PET/CT scans using the 18F-fluorothymidine tracer with routine staging 18F-FDG PET/CT scans found that 18F-FLT allowed for monitoring of changes in the cellular spread of nonsmall-cell lung cancer during chemo-radiotherapy. The findings show that the 18F-FLT tracer could be useful in improving NSCLC treatments based on patients' response.

View Full Article in:

HealthImaging.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC